Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries CLASS ACTION UPDATE for CRMD, SAVA and HNST: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders By: Levi & Korsinsky, LLP via AccessWire September 20, 2021 at 05:50 AM EDT NEW YORK, NY / ACCESSWIRE / September 20, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.CRMD Shareholders Click Here: https://www.zlk.com/pslra-1/cormedix-inc-loss-submission-form?prid=19698&wire=1SAVA Shareholders Click Here: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19698&wire=1HNST Shareholders Click Here: https://www.zlk.com/pslra-1/the-honest-company-inc-loss-submission-form?prid=19698&wire=1* ADDITIONAL INFORMATION BELOW *CorMedix Inc. (NASDAQ:CRMD)CRMD Lawsuit on behalf of: investors who purchased October 16, 2019 - May 13, 2021Lead Plaintiff Deadline : September 20, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cormedix-inc-loss-submission-form?prid=19698&wire=1According to the filed complaint, during the class period, CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Cassava Sciences, Inc. (NASDAQ:SAVA)SAVA Lawsuit on behalf of: investors who purchased February 2, 2021 - August 24, 2021Lead Plaintiff Deadline : October 26, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19698&wire=1According to the filed complaint, during the class period, Cassava Sciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.The Honest Company, Inc. (NASDAQ:HNST)This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Honest common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's May 2021 initial public offering.Lead Plaintiff Deadline : November 15, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/the-honest-company-inc-loss-submission-form?prid=19698&wire=1According to the filed complaint, (1) prior to the Initial Public Offering ("IPO"), the Company's results had been significantly impacted by a multimillion-dollar COVID-19 stock-up for products in the Diapers and Wipes category and Household and Wellness category; (2) at the time of the IPO, the Company was experiencing decelerating demand for such products; (3) as a result, the Company's financial results would likely be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.Eduard Korsinsky, Esq.55 Broadway, 10th FloorNew York, NY 10006jlevi@levikorsinsky.comTel: (212) 363-7500Fax: (212) 363-7171www.zlk.comSOURCE: Levi & Korsinsky, LLPView source version on accesswire.com: https://www.accesswire.com/664725/CLASS-ACTION-UPDATE-for-CRMD-SAVA-and-HNST-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
CLASS ACTION UPDATE for CRMD, SAVA and HNST: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders By: Levi & Korsinsky, LLP via AccessWire September 20, 2021 at 05:50 AM EDT NEW YORK, NY / ACCESSWIRE / September 20, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.CRMD Shareholders Click Here: https://www.zlk.com/pslra-1/cormedix-inc-loss-submission-form?prid=19698&wire=1SAVA Shareholders Click Here: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19698&wire=1HNST Shareholders Click Here: https://www.zlk.com/pslra-1/the-honest-company-inc-loss-submission-form?prid=19698&wire=1* ADDITIONAL INFORMATION BELOW *CorMedix Inc. (NASDAQ:CRMD)CRMD Lawsuit on behalf of: investors who purchased October 16, 2019 - May 13, 2021Lead Plaintiff Deadline : September 20, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cormedix-inc-loss-submission-form?prid=19698&wire=1According to the filed complaint, during the class period, CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Cassava Sciences, Inc. (NASDAQ:SAVA)SAVA Lawsuit on behalf of: investors who purchased February 2, 2021 - August 24, 2021Lead Plaintiff Deadline : October 26, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19698&wire=1According to the filed complaint, during the class period, Cassava Sciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.The Honest Company, Inc. (NASDAQ:HNST)This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Honest common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's May 2021 initial public offering.Lead Plaintiff Deadline : November 15, 2021TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/the-honest-company-inc-loss-submission-form?prid=19698&wire=1According to the filed complaint, (1) prior to the Initial Public Offering ("IPO"), the Company's results had been significantly impacted by a multimillion-dollar COVID-19 stock-up for products in the Diapers and Wipes category and Household and Wellness category; (2) at the time of the IPO, the Company was experiencing decelerating demand for such products; (3) as a result, the Company's financial results would likely be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.Eduard Korsinsky, Esq.55 Broadway, 10th FloorNew York, NY 10006jlevi@levikorsinsky.comTel: (212) 363-7500Fax: (212) 363-7171www.zlk.comSOURCE: Levi & Korsinsky, LLPView source version on accesswire.com: https://www.accesswire.com/664725/CLASS-ACTION-UPDATE-for-CRMD-SAVA-and-HNST-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders